A soluble activin type IIA receptor mitigates the loss of femoral neck bone strength and cancellous bone mass in a mouse model of disuse osteopenia.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Bone

• Publication date

  2018-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.bone.2018.02.026PMID 29499419
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease.

  2017cited by this paper
• Soluble activin type IIB receptor improves fracture healing in a closed tibial fracture mouse model

  2017cited by this paper
• RAP‐011 augments callus formation in closed fractures in rats

  2016cited by this paper
• Does Activin Receptor Blockade by Bimagrumab (BYM338) Pose Detrimental Effects on Bone Healing in a Rat Fibula Osteotomy Model?

  2016cited by this paper
• Sclerostin Blockade—A Dual Mode of Action After All?

  2016cited by this paper
• Anabolic action of parathyroid hormone (PTH) does not compromise bone matrix mineral composition or maturation.

  2016cited by this paper
• Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies

  2015cited by this paper
• RAP‐011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice

  2015cited by this paper
• Macrophages from the synovium of active rheumatoid arthritis exhibit an activin A‐dependent pro‐inflammatory profile

  2015cited by this paper
• Immobilization induced osteopenia is strain specific in mice

  2015cited by this paper
• Development of novel activin-targeted therapeutics.

  2015cited by this paper
• RAP-011 improves erythropoiesis in zebrafish model of Diamond-Blackfan anemia through antagonizing lefty1.

  2015cited by this paper
• Additive effect of PTH (1-34) and zoledronate in the prevention of disuse osteopenia in rats.

  2014cited by this paper
• A myostatin and activin decoy receptor enhances bone formation in mice.

  2014cited by this paper
• Sotatercept in patients with osteolytic lesions of multiple myeloma

  2014cited by this paper
• An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin

  2014cited by this paper
• Growth hormone mitigates loss of periosteal bone formation and muscle mass in disuse osteopenic rats.

  2014cited by this paper
• An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia

  2014cited by this paper
• Muscle protein synthesis, mTORC1/MAPK/Hippo signaling, and capillary density are altered by blocking of myostatin and activins.

  2013cited by this paper
• Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy

  2013cited by this paper
• Multiple‐dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA‐IgG1), a novel erythropoietic agent, in healthy postmenopausal women

  2013cited by this paper
• Increased muscle force production and bone mineral density in ActRIIB-Fc-treated mature rodents.

  2013cited by this paper
• An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy

  2013cited by this paper
• Loss of Bone Strength is Dependent on Skeletal Site in Disuse Osteoporosis in Rats

  2012cited by this paper
• Activin receptor signaling: a potential therapeutic target for osteoporosis.

  2012cited by this paper
• Guidelines for assessment of bone microstructure in rodents using micro–computed tomography

  2010cited by this paper
• Inhibiting activin‐A signaling stimulates bone formation and prevents cancer‐induced bone destruction in vivo

  2010cited by this paper
• Mechanism of action of strontium ranelate: what are the facts?

  2010cited by this paper
• A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health.

  2010cited by this paper
• Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

  2010cited by this paper
• Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis).

  2010cited by this paper
• A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys.

  2010cited by this paper
• Single‐Dose, Randomized, Double‐Blind, Placebo‐Controlled Study of ACE‐011 (ActRIIA‐IgG1) in Postmenopausal Women

  2009cited by this paper
• A soluble activin Type IIA receptor induces bone formation and improves skeletal integrity

  2008cited by this paper
• Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia

  2007cited by this paper
• The effects of combination of alendronate and human parathyroid hormone(1-34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL/6J mice.

  2007cited by this paper
• Bisphosphonates

  2006cited by this paper
• Co‐Treatment of PTH With Osteoprotegerin or Alendronate Increases Its Anabolic Effect on the Skeleton of Oophorectomized Mice

  2006cited by this paper
• Botox induced muscle paralysis rapidly degrades bone.

  2006cited by this paper
• Regulation of muscle growth by multiple ligands signaling through activin type II receptors.

  2005cited by this paper
• Smad transcription factors.

  2005cited by this paper
• Effects of Cyclic Versus Daily hPTH(1‐34) Regimens on Bone Strength in Association With BMD, Biochemical Markers, and Bone Structure in Mice

  2005cited by this paper
• Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

  2005cited by this paper
• Simvastatin treatment partially prevents ovariectomy-induced bone loss while increasing cortical bone formation.

  2004cited by this paper
• RANKL-induced DC-STAMP Is Essential for Osteoclastogenesis

  2004cited by this paper
• Myostatin Signals through a Transforming Growth Factor β-Like Signaling Pathway To Block Adipogenesis

  2003cited by this paper
• Activin A Increases the Bone Mass of Grafted Bone in C3H/HeJ Mice

  2002cited by this paper
• Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures.

  2002cited by this paper
• Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

  2001cited by this paper
• Texture analysis of X-ray radiographs is a more reliable descriptor of bone loss than mineral content in a rat model of localized disuse induced by the Clostridium botulinum toxin.

  2001cited by this paper
• How cells read TGF-beta signals.

  2000cited by this paper
• Activin A is an essential cofactor for osteoclast induction.

  2000cited by this paper
• Activin signal transduction pathways.

  2000cited by this paper
• How cells read TGF-β signals

  2000cited by this paper
• Signaling of transforming growth factor-beta family members through Smad proteins.

  2000cited by this paper
• Signaling of transforming growth factor‐β family members through Smad proteins

  2000cited by this paper
• Local administration of activin promotes fracture healing in the rat fibula fracture model.

  1999cited by this paper
• Inhibitory effects of activin‐a on osteoblast differentiation during cultures of fetal rat calvarial cells

  1999cited by this paper
• Activin A: a novel player and inflammatory marker in inflammatory bowel disease?

  1997cited by this paper
• Effect of local injection of activin A on bone formation in newborn rats.

  1994cited by this paper
• Activin enhances osteoclast-like cell formation in vitro.

  1993cited by this paper
• Functional regulation of osteoblastic cells by the interaction of activin-A with follistatin.

  1992cited by this paper
• Bovine bone activin enhances bone morphogenetic protein-induced ectopic bone formation.

  1992cited by this paper
• Novel activin receptors: distinct genes and alternative mRNA splicing generate a repertoire of serine/threonine kinase receptors.

  1992cited by this paper
• Expression cloning of an activin receptor, a predicted transmembrane serine kinase.

  1991cited by this paper
• The nucleator

  1988cited by this paper
• The efficiency of systematic sampling in stereology and its prediction *

  1987cited by this paper
• Isolation and partial characterization of follistatin: a single-chain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone.

  1987cited by this paper
• Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid

  1986cited by this paper
• Isolation and partial characterization of a Mr 32,000 protein with inhibin activity from porcine follicular fluid.

  1985cited by this paper
• The FASEB Journal • Research Communication The activin A-follistatin system: potent regulator of human extracellular matrix mineralization

  year unknowncited by this paper

• High-fat diet induced obesity and anti-activin receptor antibody: Effects on bone properties in mice

  2025cites this paper
• From bench to bedside: The promise of sotatercept in hematologic disorders.

  2023cites this paper
• Pharmaceutical treatment of bone loss: From animal models and drug development to future treatment strategies.

  2023cites this paper
• Activins, follistatins and inhibins in postmenopausal osteoporosis: A proof of concept, case-control study.

  2022cites this paper
• Botulinum Toxin A and Osteosarcopenia in Experimental Animals: A Scoping Review

  2021cites this paper
• Osteoporosis associated with chronic kidney disease

  2021cites this paper
• Bone Geometry Is Altered by Follistatin‐Induced Muscle Growth in Young Adult Male Mice

  2021cites this paper
• Principles of the activin receptor signaling pathway and its inhibition.

  2021cites this paper
• Short-term glucocorticoid excess blunts abaloparatide-induced increase in femoral bone mass and strength in mice

  2021cites this paper
• Activin type IIA decoy receptor and intermittent parathyroid hormone in combination overturns the bone loss in disuse-osteopenic mice.

  2020cites this paper
• Inhibition of the activin receptor signaling pathway: A novel intervention against osteosarcoma

  2020cites this paper
• A multi-omics approach expands the mutational spectrum of MAP2K1-related melorheostosis.

  2020cites this paper
• Emerging therapeutic targets for osteoporosis

  2020cites this paper
• Disuse-induced loss of bone mineral density and bone strength is attenuated by post-lactational bone gain in NMRI mice.

  2019cites this paper
• A follistatin‐based molecule increases muscle and bone mass without affecting the red blood cell count in mice

  2019cites this paper